

## State of Oklahoma SoonerCare

Fulphila<sup>®</sup> (Pegfilgrastim-jmdb), Nivestym<sup>®</sup> (Filgrastim-aafi), Neulasta<sup>®</sup> (Pegfilgrastim), Releuko<sup>™</sup> (Filgrastim-ayow), and Udenyca<sup>®</sup> (Pegfilgrastim-cbqv)

Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	h
□Physician billing (HCPCS code:	) □Pharmacy	billing (NDC:)
Dose: Dosing Regimen: Start Date (or date of next dose):		
Expected Treatment Duration/Number of Doses:		
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fa	ax:
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
Criteria Cri		
Granix <sup>®</sup> (tbo-filgrastim), I (filgrastim-sndz), or Ziex	-specific, clinically significar Neupogen <sup>®</sup> (filgrastim), Nyv tenzo <sup>®</sup> (pegfilgrastim-bmez	nt reason why the member cannot use vepria™ (pegfilgrastim-apgf), Zarxio®
information:  A. Diagnosis:  B. Please provide a patient Granix® (tbo-filgrastim), I		
Prescriber Signature:  I certify that the indicated treatment the best of my knowledge.	nt is medically necessary	Date: and all information is true and correct to if necessary. Failure to complete this form in full will

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 208 8/25/2022